Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Net Issuance of Common Stock
Gensight Biologics SA
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Net Issuance of Common Stock
€16.5m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Net Issuance of Common Stock
€57.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Net Issuance of Common Stock
€140k
|
CAGR 3-Years
8%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
-46%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Net Issuance of Common Stock
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Net Issuance of Common Stock
€28.1m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
326%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Net Issuance of Common Stock
-€2.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Net Issuance of Common Stock?
Net Issuance of Common Stock
16.5m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Net Issuance of Common Stock amounts to 16.5m EUR.
What is Gensight Biologics SA's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
16%
Over the last year, the Net Issuance of Common Stock growth was 16 368%. The average annual Net Issuance of Common Stock growth rates for Gensight Biologics SA have been -32% over the past three years , 16% over the past five years .
You don't have any saved screeners yet